OGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - The allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of over 70% in the quarterly dividend payout [4]. - Following the announcement of the reduced dividend from $0.28 to$0.02 on May 1, 2025, Organon's stock price fell by more than 27% [5]. Group 2: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - The company had previously reported optimistic dividend payouts, which were later contradicted by a newly implemented debt reduction strategy following the acquisition of Dermavant Sciences Ltd [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].